Endostart Appoints Christopher Rowland Chairman of the Company’s Board of Directors.
15.7.2022 09:00:00 EEST | Business Wire | Press release
The growth of Italian medical device start-up Endostart continues with the appointment of Christopher Rowland, a global expert in the medical device industry, to Chairman of the company’s Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220714005706/en/
Endostart is proud to announce the appointment of Chris Rowland as Chairman of the company’s Board of Directors. Chris is a well-known expert in the medical device industry global market and joins Endostart with over 30 years of experience in sales, product development, marketing, business development, and executive leadership in the US and abroad. His unrivalled experience and business competency will be crucial as we commercialize our innovative medical device to improve the colonoscopy experience for physicians, patients, and the entire health care system. (Photo: Business Wire)
With over 30 years of experience in positions of increasing responsibility in sales, product development, marketing, business development, and CEO leadership in the US and abroad, Chris brings an unrivaled experience and competency in a wide variety of clinical and commercial medical devices verticals, including gastroenterology, cardiology, urology, radiology, and peripheral vascular specialties.
His professional experience includes 17 years with Boston Scientific, ending as the Global VP of Marketing for the Endoscopy Division; he also served as President of Given Imaging Inc. (acquired by Covidien/MDT) and President/CEO of Neotract Inc. (acquired by Teleflex). Chris is also currently the President and CEO of Tricol Biomedical, a leader in hemostasis technology.
In his new role, Chris will work with and coordinate the Board of Directors for Endostart.
“With his long history of leadership and his expertise in the digestive endoscopy industry, Chris is the ideal Chairman of the Board for Endostart,” said Alessandro Tozzi, CEO and founder of Endostart. “We are certain that Chris will be a driving force in our success.”
“I am excited to support the investors and the leadership team of this dynamic company. I believe Endostart is poised for significant growth reflecting demand for its innovative products to enhance endoscopic performance,” said Mr. Rowland. “I look forward to helping Endostart maximize shareholder value and realize its commercial potential.”
About Endorail™
The first product from Endostart is Endorail™, an innovative medical device aimed at facilitating completion of colonoscopy procedures using Magnetic Balloon Technology. This technology is designed to enhance endoscope performance and enable endoscopists to easily achieve quality standards. Endorail received a CE mark in 2019 and has been tested in a clinical setting. It is not yet cleared by the US Food and Drug Administration (FDA).
About Endostart
Founded in 2018, Endostart is focused on developing and manufacturing next-generation medical devices for gastrointestinal endoscopy. The company is ISO 13485 certified. It has an international board of directors and a strong medical advisory board. It recently announced a capital increase of €8.2M (USD $10M).
Website: www.endostart.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005706/en/
Contact information
Contact: info@endostart.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 04:00:00 EEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe ’s Coverage of ESCMID Global Congress 202617.7.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 01:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-treat, high-impact sites, including the scalp, nails, palms and soles, compared with placebo.1-5 These data build on the topline results from the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled LATITUDE PsO 3001 and 3002 studies.2,6 In those studies, about 70% of patients treated with zasocitinib achieved static Physician Global Assessment (sPGA) 0/1 (clear or almost clear skin) at week 16, with a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate seen as early as w
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance17.7.2026 00:36:00 EEST | Press release
The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful placement, Merz has further diversified its funding base by
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 23:22:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom